The Wall Street Journal·1 min read·medium
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand - WSJ
W
WSJ✦AI Summary
Eli Lilly reported increased revenue driven by sustained high demand for its GLP-1 weight-loss and diabetes medications. The company continues to see strong market performance in this pharmaceutical sector.
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in